Castle Biosciences, Inc.

XNASHealth care

Last traded price · USD

$35.14

−1.72%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 22:45 IST · A quote does not mean the product is available to trade on your account.

Day's open: $35.17
Previous close: $35.75
Volume: 153,221
Day's high: $35.71
Day's low: $34.56

In brief

Castle Biosciences, Inc. is a health care company listed on Nasdaq, valued at about $1.07B.
Its shares closed at $35.75 on 4 Nov 2026, up 13.0% over the past year.
From India you can buy CSTL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Castle Biosciences, Inc. (CSTL) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole CSTL share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade CSTL options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

In line with SPY, behind its sector fund XLV over 1 year
1 month: +7.2% (SPY −1.6%, XLV +13.5%). 3 months: +17.6% (SPY −0.4%, XLV +15.5%). 1 year: +13.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CSTL, SPY and XLV · as of 4 Nov 2026
6.0 days to cover short interest
2.0M shares were sold short at the 15 Oct 2026 settlement, 6.6% of the 30.5M shares outstanding; covering them would take 6.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.0× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 723.8K shares was 2.0× the average of the 30 sessions before it (357.5K), as the price rose 5.0%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $35.75 was 4.3% above its 50-day average ($34.28) and 25.7% above its 200-day average ($28.45). It has closed above the 200-day for 55 sessions, since 19 Aug 2026. The 50-day average crossed above the 200-day on 15 Sep 2026, 36 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
68% of the way up its 52-week range
Closed at $35.75 on 4 Nov 2026: 19.3% below the 52-week high of $44.28 (26 Jan 2026) and 101.7% above the low of $17.72 (14 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+7.2%

6 months+44.4%

1 year+13.0%

5 years−40.3%

Newswire

About

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Website

Notable moves

August 5, 2025
+32.83%
July 7, 2023
+52.86%
June 5, 2023
−48.70%

Newswire

About

Website

Notable moves

August 5, 2025
+32.83%
July 7, 2023
+52.86%
June 5, 2023
−48.70%

Castle Biosciences, Inc.

XNASHealth care

Last traded price · USD

$35.14

−1.72%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 22:45 IST · A quote does not mean the product is available to trade on your account.

Day's open: $35.17
Previous close: $35.75
Volume: 153,221
Day's high: $35.71
Day's low: $34.56

In brief

Castle Biosciences, Inc. is a health care company listed on Nasdaq, valued at about $1.07B.
Its shares closed at $35.75 on 4 Nov 2026, up 13.0% over the past year.
From India you can buy CSTL in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Castle Biosciences, Inc. (CSTL) shares from India?

Do I need the price of a whole CSTL share to invest?

How much can I invest in US stocks in a year?

Can I trade CSTL options or futures?

Insights

Quotes run fifteen minutes behind.

In line with SPY, behind its sector fund XLV over 1 year
1 month: +7.2% (SPY −1.6%, XLV +13.5%). 3 months: +17.6% (SPY −0.4%, XLV +15.5%). 1 year: +13.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CSTL, SPY and XLV · as of 4 Nov 2026
6.0 days to cover short interest
2.0M shares were sold short at the 15 Oct 2026 settlement, 6.6% of the 30.5M shares outstanding; covering them would take 6.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.0× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 723.8K shares was 2.0× the average of the 30 sessions before it (357.5K), as the price rose 5.0%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $35.75 was 4.3% above its 50-day average ($34.28) and 25.7% above its 200-day average ($28.45). It has closed above the 200-day for 55 sessions, since 19 Aug 2026. The 50-day average crossed above the 200-day on 15 Sep 2026, 36 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
68% of the way up its 52-week range
Closed at $35.75 on 4 Nov 2026: 19.3% below the 52-week high of $44.28 (26 Jan 2026) and 101.7% above the low of $17.72 (14 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+7.2%

6 months+44.4%

1 year+13.0%

5 years−40.3%

Newswire

About

Website

Notable moves

August 5, 2025
+32.83%
July 7, 2023
+52.86%
June 5, 2023
−48.70%

Newswire

About

Website

Notable moves

August 5, 2025
+32.83%
July 7, 2023
+52.86%
June 5, 2023
−48.70%

Castle Biosciences, Inc.

Castle Biosciences, Inc. in brief

In line with SPY, behind its sector fund XLV over 1 year

6.0 days to cover short interest

Volume 2.0× its 30-session average on 29 Oct 2026

Above its 50- and 200-day averages

68% of the way up its 52-week range

Castle Biosciences, Inc.

Castle Biosciences, Inc. in brief

In line with SPY, behind its sector fund XLV over 1 year

6.0 days to cover short interest

Volume 2.0× its 30-session average on 29 Oct 2026

Above its 50- and 200-day averages

68% of the way up its 52-week range